Latest stories on GRAL
GRAIL to Present at the UBS Global Healthcare Conference
StockTitan53 · neutralproduct/pr
5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
MarketBeat58 · neutralgeneral
GRAIL to Announce Third Quarter 2026 Financial Results
PR Newswire50 · neutralearnings
Liquid Biopsy Market Research to Reach USD 27.42 Billion by 2035 as Cancer Blood Tests, AI Diagnostics and Precision Oncology Advance
GlobeNewswire58 · neutralproduct/pr
Grail price target raised to $180 from $88 at TD Cowen
The Fly74 · bullishanalyst
Grail price target raised to $225 from $215 at TD Cowen
The Fly63 · neutralanalyst
TD Cowen raises Grail stock price target to $180 on FDA outlook
Investing.com Analyst Ratings67 · bullishanalyst
Grail price target raised to $120 from $60 at Morgan Stanley
The Fly74 · bullishanalyst
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
The Motley Fool63 · neutralgeneral
2 Growth Stocks to Buy in October
The Motley Fool63 · neutralanalyst
Why CVS Is ‘Insanely Cheap,’ ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase
24/7 Wall St.57 · neutralanalyst
Grail is a long way from being profitable, says Jim Cramer
CNBC42 · neutralgeneral
The one thing I am worried about here is the valuation, says Jim Cramer on Grail
CNBC48 · neutralanalyst
This buzzy biotech stock is up 60% this year. Cramer's advice on building a stake
CNBC67 · bullishanalyst
GRAIL spotlights Galleri’s “more than 200 cancers” data ahead of two major October conferences
October 6, 2026
MarketChameleon63 · neutralproduct/pr
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
GlobeNewswire56 · neutralgeneral
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Business Insider56 · neutralgeneral
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026
PR Newswire63 · neutralproduct/pr
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?
The Motley Fool67 · bullishgeneral
Grail price target raised to $175 from $105 at UBS
The Fly69 · bullishanalyst
A Cancer Test Has Investors Betting Big. But Will Insurers Pay?
WSJ Markets58 · neutralproduct/pr
Lightning Round: Grail can go higher, says Jim Cramer
CNBC63 · neutralanalyst
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October
The Motley Fool73 · bullishanalyst
Why Grail Stock Skyrocketed Nearly 70% In A Week. What To Watch Next.
Investors.com73 · bullishgeneral